Frida S. Boer-Pérez

Frida S. Boer-Pérez

Auto-generated profile, based on publicly available information

Frida S. Boer-Pérez

Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
FBFrida S. Boer-Pérez
Frida S. Boer-Pérez
VLVictoria Lima-Rogel
Victoria Lima-Rogel
SRSilvia Romano-Moreno
Silvia Romano-Moreno
AMAna Ruth Mejia-Elizondo
Ana Ruth Mejia-Elizondo
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
RMRosa del Carmen Milán-Segovia
Rosa del Carmen Milán-Segovia
Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age ≤28 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chromatography with tandem mass spectrometry method. Population pharmacokinetic analysis for piperacillin was performed using nonlinear mixed-effects modeling. A total of 65 blood samples were collected from 25 neonates, both preterm (56%) and full-term. Piperacillin pharmacokinetics was best described by a one-compartment model incorporating body weight-based allometric scaling, postmenstrual age, and serum creatinine as covariates influencing clearance. For a typical neonate in the study (1.76 kg), the estimated clearance was 0.748 L/h (coefficient of variation, 38.3%), and the volume of distribution was 0.866 L (37.7%). Simulations indicated adequate probability of target attainment with current recommendations, but a high proportion of preterm neonates (>75%) were at risk of overexposure (trough piperacillin plasma concentration >50 mg/L). Additional simulations supported individualized initial regimens based on renal maturation and suggested that extended infusions (1−4 h) may improve target attainment for stricter targets and less-susceptible pathogens. This study provides a validated pharmacokinetic model for piperacillin in neonates with severe infections, offering a framework to optimize empiric dosing based on renal function and developmental stage.

1 July 2024 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
FBFrida S. Boer-Pérez
Frida S. Boer-Pérez
VLVictoria Lima-Rogel
Victoria Lima-Rogel
AMAna Ruth Mejia-Elizondo
Ana Ruth Mejia-Elizondo
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
ARAna S. Rodríguez-Báez
Ana S. Rodríguez-Báez
SRSilvia Romano-Moreno
Silvia Romano-Moreno